Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia by Broderick, Carolyn R et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Blood Disorders
Open Access Study protocol
Estimation of transient increases in bleeding risk associated with 
physical activity in children with haemophilia
Carolyn R Broderick*1,2,3, Robert D Herbert3, Jane Latimer3, Chris Barnes4, 
Julie A Curtin5 and Paul Monagle4,6
Address: 1School of Medical Sciences, University of New South Wales, Randwick NSW 2052, Australia, 2Children's Hospital Institute of Sports 
Medicine, The Children's Hospital at Westmead, Westmead NSW 2145, Australia, 3The George Institute for International Health, Camperdown 
NSW 2050, Australia, 4Department of Haematology Royal Children's Hospital, Parkville VIC 3052, Australia, 5Department of Haematology, The 
Children's Hospital at Westmead, Westmead NSW 2145, Australia and 6Department of Pathology, University of Melbourne Parkville, VIC 3052, 
Australia
Email: Carolyn R Broderick* - c.broderick@unsw.edu.au; Robert D Herbert - rherbert@george.org.au; Jane Latimer - jlatimer@george.org.au; 
Chris Barnes - chris.barnes@rch.org.au; Julie A Curtin - juliec3@chw.edu.au; Paul Monagle - paul.monagle@rch.org.au
* Corresponding author    
Abstract
Background: Although it is widely appreciated that vigorous physical activity can increase the risk
of bleeding episodes in children with haemophilia, the magnitude of the increase in risk is not
known. Accurate risk estimates could inform decisions made by children with haemophilia and their
parents about participation in physical activity and aid the development of optimal prophylactic
schedules. The aim of this study is to provide an accurate estimate of the risks of bleeding
associated with vigorous physical activity in children with haemophilia.
Methods/Design: The study will be a case-crossover study nested within a prospective cohort
study. Children with moderate or severe haemophilia A or B, recruited from two paediatric
haematology departments in Australia, will participate in the study. The child, or the child's parent
or guardian, will report bleeding episodes experienced over a 12-month period. Following a
bleeding episode, the participant will be interviewed by telephone about exposures to physical
activity in the case period (8 hours before the bleed) and 2 control periods (an 8 hour period at
the same time on the day preceding the bleed and an 8 hour period two days preceding the bleed).
Conditional logistic regression will be used to estimate the risk of participating in vigorous physical
activity from measures of exposure to physical activity in the case and control periods.
Discussion: This case-control study will provide estimates of the risk of participation in vigorous
physical activity in children with haemophilia.
Background
Haemophilia affects 1 in 7,000 males in Australia.[1]
Clinically, haemophilia is characterised by bleeds, most
often into muscles or joints. Some children with hemo-
philia develop "target joints" when multiple bleeds into
the same joint lead to destruction of the joint surfaces
(haemophilic arthropathy).
Over the past decade there has been a move to treat chil-
dren with moderate and severe haemophilia prophylacti-
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cally. Typically a child may be given two to three
intravenous injections of recombinant factor VIII or IX
each week. Injections may be timed to precede vigorous
physical activity because vigorous physical activity is
thought to elevate the risk of bleeding episodes. Prophy-
lactic clotting factor injections reduce the number of
bleeding episodes, but many children with moderate and
severe haemophilia still experience bleeding episodes sev-
eral times a year.
Although it is widely believed that vigorous physical activ-
ity can increase the risk of bleeds, the magnitude of the
increase in risk is not known. Accurate estimates of the
risk of bleeding associated with physical activity would
enable the tailoring of prophylactic schedules to individ-
uals, taking into consideration fluctuations in risk.
In addition to guiding prophylactic schedules, good infor-
mation about the risks of bleeds associated with vigorous
physical activity is needed to inform the decisions made
by children with haemophilia and their parents about
participation in physical activities. Informed decisions
must be supported by good estimates of risk.
This study will provide the first estimates of the risks of
bleeding associated with vigorous physical activity in chil-
dren with haemophilia. Risk estimates can form the basis
of rational prophylactic schedules and can inform deci-
sions about participation in physical activities.
Aims
The aims of this study are, therefore, to:
(a) Quantify the transient increase in risk of bleeding
associated with vigorous physical activity in children with
haemophilia
(b) Determine whether habitual activity is associated with
the transient risk of bleeding episodes following physical
activity
(c) Determine the induction period for a bleed caused by
vigorous physical activity
Methods
Design
The study will be a case-crossover study nested within a
prospective cohort study. The case-crossover design ena-
bles quantification of the risk associated with transient
exposures. It is more efficient than cohort designs because
it samples only cases, and it is less exposed to selection
bias than case-control designs because cases provide their
own control data.
The target population is children with moderate or severe
haemophilia A or B. To be eligible to participate, children
must be aged between 4 and 18 years. Children with mild
haemophilia (i.e. factor VIII or IX levels > 5%) or von Wil-
lebrand disorder will be excluded. Children will be
recruited from two paediatric haematology departments
in Sydney and Melbourne, Australia.
The aims and methods of the study will be explained to
potential participants and their parents or guardians.
Hereafter we refer to the child or parent or guardian as the
participant. Participants will be given plain-English infor-
mation sheets and will be asked to give written consent to
participate. The study has been given ethical approval by
the Human Research Ethics Committees at the University
of Sydney, The Children's Hospital at Westmead and the
Royal Children's Hospital, Melbourne.
Procedures
Most interviews with participants will be conducted by
telephone although where it is convenient to do so some
interviews may be conducted in person. At the first inter-
view a researcher will establish whether the interview is
best conducted with the child or with the parent or guard-
ian. The researcher will record participants' contact details
and the child's characteristics, including current age, age at
diagnosis, type of bleeding disorder, severity of bleeding
disorder, estimated number of bleeds in the past 12
months, height and weight (BMI), prophylaxis schedule,
habitual activity level, orthopaedic history (including his-
tory of known arthropathy and joint arthropathy score)
and presence of neutralising antibodies or inhibitors (i.e.
inhibitor titre of 0.5 Bethesda units or more [2]). Where
necessary, and with permission from participants, these
details will be obtained from the participant's medical
record.
In addition, the participant will be asked to complete
Kriska's modifiable activity questionnaire (MAQ).[3] This
questionnaire will be administered directly to children
over 12 years of age and to both child and parent in chil-
dren less than 12 years of age. The questionnaire has been
successfully used to measure habitual activity in children
and adolescents with cystic fibrosis and has demonstrated
test-retest reliability.[4] The questionnaire enables estima-
tion of total hours of activity per week for the past year,
average intensity (expressed as MET hours/week), and
hours per week of vigorous activity (> 6 METs).
For the following year the participant will be monitored to
determine whether a bleeding episode has occurred. Par-
ticipants will be asked to notify the researchers of any
bleeds that occur. Identification of bleeding episodes by
self-report will be supplemented with two additional
mechanisms: bleeding diaries and weekly SMS messages.BMC Blood Disorders 2008, 8:2 http://www.biomedcentral.com/1471-2326/8/2
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All participants in the study will be given a bleeding diary.
The diary will record the number and site of bleeding epi-
sodes. In addition each participant will be sent weekly
SMS (text) messages. At a pre-specified time each week, a
message will be sent to the participant to ascertain if a
bleed has occurred in the past week. If no reply is received,
follow up messages will be sent 24 and 48 hours later. If
there is still no reply the participant will be contacted by
phone. For the purposes of this study we have accepted
the definition of a bleed as that widely used by other
researchers, that is, "an episode of bleeding requiring
treatment with clotting factor". [5]
If the participant reports a bleed in the preceding week the
participant will be interviewed by telephone as soon as
possible after the bleed. The timing of the interview and
the bleed will be documented. The interviewer will con-
struct an "activity clock" spanning the case and control
periods. Information will be sought about the number,
site, severity and timing of bleeds, treatment given, details
of clotting factor injections administered over the previ-
ous two weeks, and details of any additional medication.
This will provide information about:
• physical activity in the 8 hours immediately preceding
the bleed (exposure in the case period)
￿ physical activity in the period 32-24 hours preceding the
bleed (exposure in the first control period)
￿ physical activity in the period 56-48 hours preceding the
bleed (exposure in the second control period)
Physical activity occurring in the case and control periods
will be assigned to one of three categories reflecting the
frequency and severity of collisions that children are
expected to experience while participating in the activity.
The categories will be based on those used by the Ameri-
can National Hemophilia Association in their popular
brochure titled Hemophilia Sport and Exercise. Some addi-
tional activities (such as Australian Rules Football and
netball) will be added to make the categories suitable for
use with Australian populations. Category 1 activities are
non-contact activities such as swimming and table tennis.
(Walking will be excluded because it is ubiquitous and
quantifying the risk of bleeding associated with walking is
not of interest.) Category 2 activities involve limited con-
tact such as soccer. Category 3 activities are those in which
contact and collisions are inevitable (such as rugby). In
addition questions will be asked about factors that are
probably not risk factors. These data will be used in sec-
ondary analyses described below.
On many occasions the child will have experienced no
bleeding episodes in the preceding week so an interview
will not be required. Children who have already experi-
enced a bleeding episode since entering the study will
continue to be called weekly. The same procedures will be
followed if there is a subsequent bleed, except if the sub-
sequent bleeding episode occurs within a fortnight of a
previous episode. In that case, the bleed will be counted
for the purpose of documenting incidence of bleeds, but
will be ignored when quantifying the risk of bleeds asso-
ciated with physical activity.
On one occasion randomly selected during the year, par-
ticipants will be contacted by telephone and asked the
same questions about exposure to physical activity as they
were asked following bleeds. These data will be used for
the crossover-control analysis described below. Interviews
conducted after bleeds may be hours or even days after the
bleed, which means that interviews conducted after bleeds
seek data about exposure periods the most recent of which
was hours or even days prior to the interview. Conse-
quently when conducting the interviews at randomly
selected times (not after a bleed) participants will be asked
about exposure periods, the most recent of which was
hours or even days prior to the interview. At the same
interview, participants will be asked to prospectively
record all activity in the following week. This will provide
prospectively collected data about the usual frequency of
exposure that can be used in a usual frequency analysis.
Methods that could be used to blind participants and
research assistants to the study aims were considered, but
these methods were thought not to be effective or ethi-
cally acceptable. Blinding is desirable in case-control stud-
ies because it reduces the possibility of recall bias.
However blinding may be less important in the case-cross-
over design. In the case-crossover design participants
report exposure to physical activity in both the case and
control periods. Recall bias is most problematic if there is
differential mis-reporting in the case and control periods,
which we believe is unlikely to occur. To minimise the
possibility of reporting bias, participants will not be told
that the primary aim is to quantify risks associated specif-
ically with physical activity.
Data analysis
Conditional logistic regression will be used to estimate
the risk of participating in vigorous physical activity from
measures of exposure to physical activity in the case and
control periods. The basic regression model will be:
log odds of bleedi = ai + b.period + c.severity,
where  period  is a dummy-coded variable indicating if
exposure to activity occurred in the exposure period or
control period, and severity is a dummy-coded variable
indicating if the subject had moderate or severe haemo-BMC Blood Disorders 2008, 8:2 http://www.biomedcentral.com/1471-2326/8/2
Page 4 of 5
(page number not for citation purposes)
philia. This analysis estimates an odds ratio (eb) which
quantifies the risk of bleeding associated with vigorous
physical activity. The analysis is conditional because data
from the case period and the two control periods are
matched, and because participants can experience multi-
ple bleeds. In the primary analysis vigorous physical activ-
ity will be defined as Category 2 or 3 activities.
Consequently this analysis will provide estimates of the
risk of Category 2 or 3 activities.
In addition, the regression model will be extended to
include terms for nonlinear effects of time since factor
administration and their interactions with the period vari-
able. This controls for time since factor administration,
which we consider to be the most plausible potential con-
founder. [6] It will also provide useful information about
the time course of risks associated with physical activity
following factor administration.
In secondary analyses the risks associated with Category 1,
Category 2 and Category 3 activities will be analysed sep-
arately. In addition, a usual frequency analysis will be
conducted.[7] The usual frequency analysis will produce
an alternative risk estimate by using negative binomial
regression to contrast the incidence rate of exposures
observed in the randomly selected week with the inci-
dence rate of exposures in the case period. (If a bleeding
episode occurred in the randomly selected week then only
that part of the week more than 24 hours prior to the
bleed will contribute to the estimate of the usual inci-
dence rate of exposures).
If a participant wakes with a bleed, the time at which they
would first have noticed symptoms of the bleed had they
not been asleep is not known. Consequently an addi-
tional secondary analysis in which waking bleeds are
excluded from the analysis will be performed.
We will test the hypothesis that the risk of bleeding asso-
ciated with physical activity depends on the severity of dis-
ease by testing if an interaction term (period  ×  disease
severity) contributes significantly to the model.
Sensitivity analyses will be conducted by varying the
length of case and control periods.
Data collected at times when participants did not bleed
will be used to conduct a crossover-control analysis.[8]
The crossover-control analysis compares exposures in two
periods (a pseudo "case" period and a control period) that
do not precede a bleed; this analysis should yield a risk
estimate of approximately zero (odds ratio of ~1.0). This
provides a test of the presence of reporting bias.
Data on the usual frequency of exposure to physical activ-
ity obtained from the randomly selected week will be
combined with estimates of the transient relative risk
associated with physical activity to estimate the cumula-
tive risk associated with the usual frequency of physical
activity.
To achieve the second aim of assessing whether habitual
activity modifies the transient risk of bleeding episodes
following physical activity, terms will be entered into the
model for habitual physical activity (MAQ) measured at
baseline, as well as the period × habitual activity interaction.
The primary analyses assume that the induction period for
symptoms of a bleed caused by physical activity is less
than 8 hours. Empirical evidence of the length of the
induction period will be sought by examining histograms
of the time elapsed between the onset of symptoms of
each bleed and the last preceding occasion of physical
activity. These histograms will be compared with histo-
grams obtained from the control periods, and with the
histograms obtained when participants were interviewed
at one randomly selected occasion during the year, to
determine the period over which physical activity
appeared to contribute to an excess of bleeds (i.e. the
induction period).
Sample size calculations
The study is designed to be adequately powered for the
primary analysis, which involves estimation of the risk of
bleeding associated with physical activity. The approach
to calculating sample size was as follows. First the sample
size necessary for a paired case-control study was calcu-
lated using the procedures described by Dupont. [9] This
showed that in a conventional paired case-control design
with one event per participant we would need a sample of
210 cases (bleeds) to provide an 80% probability of
detecting an odds ratio of 2.5 assuming (a) alpha is 0.05,
(b) 20% of boys will be exposed to exercise in the control
period, and (c) the correlation between exposures in the
case and control period (phi coefficient) is 0.5. The rela-
tively large risk (odds ratio of 2.5) is justified because the
risk is only transient.
On the basis of bleeding rates observed at the Royal Chil-
dren's Hospital haemophilia clinic it was anticipated that
the participants will experience, on average, about 4
bleeding episodes per year. The sample size estimate was
therefore divided by 4 to obtain a crude estimate of the
required number of participants. Then, to allow for the
lack of independence amongst repeated bleeds, the sam-
ple size was inflated by a factor that was a function of the
estimated average number of bleeds per participant (four)
and an estimated maximum intra-class (intra-participant)
correlation (0.2). [10] This yielded a sample size of 336Publish with BioMed Central    and   every 
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bleeds. It is expected that this sample size will be achieved
with 84 participants, but the study will be terminated with
the 336th bleed, not the 84th participant.
Discussion
This project will provide the first research-based estimates
of the risk of bleeding episodes associated with vigorous
physical activity in children with haemophilia. These risk
estimates can be used to inform decisions about participa-
tion in vigorous physical activities. Estimates of the risks
of bleeds associated with particular categories of physical
activity can be used to appropriately weigh risks and ben-
efits of participation in vigorous physical activities. The
design of optimal prophylactic schedules requires infor-
mation about the magnitude of the fluctuations in risk
associated with physical activity. Good risk data can there-
fore be used to optimise prophylactic strategies.
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